Consensus statement

Statement of the 3rd International Exercise-Associated Hyponatremia Consensus Development Conference, Carlsbad, California, 2015

Tamara Hew-Butler,1 Mitchell H Rosner,2 Sandra Fowkes-Godek,3 Jonathan P Dugas,4 Martin D Hoffman,5 Douglas P Lewis,6 Ronald J Maughan,7 Kevin C Miller,8 Scott J Montain,9 Nancy J Rehrer,10 William O Roberts,11 Ian R Rogers,12 Arthur J Siegel,13 Kristin J Stuempe14, James M Winger,15 Joseph G Verbalis16

INTRODUCTION

The 3rd International Exercise-Associated Hyponatremia (EAH) Consensus Development Conference convened in Carlsbad, California, in February 2015, with a panel of 17 international experts. The delegates represented four countries and nine medical and scientific subspecialties pertaining to athletic training, exercise physiology, sports medicine, water/sodium metabolism and body fluid homeostasis. The primary goal of the panel was to review the existing data on EAH and update the 2008 Consensus Statement.1 This document serves to replace the 2nd International EAH Consensus Development Conference Statement and launch an educational campaign designed to address the morbidity and mortality associated with a preventable and treatable fluid imbalance.

The following statement is a summary of the data synthesised by the 2015 EAH Consensus Panel and represents an evolution of the most current knowledge on EAH. This document will summarise the most current information on the prevalence, aetiology, diagnosis, treatment and prevention of EAH for medical personnel, athletes, athletic trainers and the greater public. The EAH Consensus Panel strove to clearly articulate what we agreed on, did not agree on and did not know, including minority viewpoints that were supported by clinical experience and experimental data. Further updates will be necessary to: (1) remain current with our understanding and (2) critically assess the effectiveness of our present recommendations. Suggestions for future research and educational strategies to reduce the incidence and prevalence of EAH are provided at the end of the document; areas of controversy that remain in this topic have also been outlined.

CONSENSUS METHODOLOGY

The 3rd International EAH Consensus Development Conference utilised National Institutes of Health guidelines, amended for a more holistic approach to fit the needs of both the group and the topic. Twenty-two individuals (17 accepted) were invited to participate in the consensus conference who: (1) have made scientific and/or clinical contributions to the topic of water and sodium homeostasis, and/or hyponatraemia; and (2) represented a specific group (eg, nephrology, endurance medicine, etc) or had unique topical expertise (eg, cystic fibrosis (CF), muscle cramps, fluid balance, etc). The present document is intended to serve as the scientific record of the conference with intent to widely disseminate this information to achieve maximum impact on both current healthcare practice and future medical research.

The methodology governing the conduct of this consensus development conference is summarised below.

▸ A broad-based expert panel was assembled. Panel members included researchers and clinicians in endocrinology (JGV), nephrology (MHR), emergency medicine (IRR), family medicine (WOR, JMW and DPL), internal medicine (AJS), physical medicine and rehabilitation (MDH), sports medicine (WOR, JMW and DPL), athletic training (SF-G and KCM) and exercise physiology (JP, SF-G, TH-B, MDH, RJM, SJM, NJR and KJS).

▸ These experts presented data on EAH in a day long public session, followed by open question/answer and discussion periods with the audience. The panel members met the following day in a closed session to prepare the consensus statement.

▸ Workgroups were created 3 months prior to the February 2015 meeting to update the following EAH target areas: epidemiology, aetiology and pathophysiology, diagnosis, treatment and prevention. Each workgroup was asked to present updated drafts for discussion during the closed session.

▸ A systematic, comprehensive and updated literature review was shared by the panel members prior to the February 2015 meeting, using a cloud storage service that was organised into workgroup categories (epidemiology, aetiology and pathophysiology, diagnosis, treatment and prevention). All panel members had unlimited access to the cloud storage service and could add digital versions of published manuscripts to the EAH manuscript section at any time.

The panel chairperson (MHR) was responsible for monitoring the progress of each work group, directing the closed session and guiding the panel’s deliberations. Using the previous two EAH consensus statements as a starting point, each work group was asked to: (1) incorporate new data into each assigned section and (2) update any outdated information. All recommendations were graded based on clinical strength, using the grading scale described by the American College of Chest Physicians (table 1).17 Particular emphasis was placed on...
creating more generalised recommendations so as to prevent and treat EAH across a wider variety of athletic events, rather than the endurance sports focus of the two prior EAH Consensus Statements.

SPONSORSHIP
The travel (except RJM and IRR, who supported their own travel), hotel and meal expenses for the participants were funded by CrossFit, Inc. The open conference was also sponsored by CrossFit, Inc. However, no members from CrossFit, Inc, participated in any of the closed discussions or contributed to the development of the consensus guidelines. Furthermore, no members from CrossFit, Inc, had access to the consensus document prior to publication.

RESULTS AND DISCUSSION

Definition
EAH is used to describe hyponatraemia occurring during or up to 24 h after physical activity. It is defined by a serum, plasma or blood sodium concentration ([Na⁺]) below the normal reference range of the laboratory performing the test. For most laboratories, this is a [Na⁺] less than 135 mmol/L.² The main determinants of the serum [Na⁺] are the total content of exchangeable body sodium and potassium relative to total body water and thus hyponatraemia can result from loss of solutes (sodium, potassium), a relative excess of total body water or a combination of both.³ ⁴ However, in most clinical scenarios, the driving force for the development of hyponatraemia is a relative excess of total body water.⁵ ⁶ The symptoms associated with EAH depend on both the magnitude of the serum sodium decrease from baseline level along with the rate at which this decrease occurs. Symptomatic EAH can occur if the rate of fall approaches 7–10% within 24 h.⁷ Thus, more severe degrees of hyponatraemia (typically <125 mmol/L) as well as more modest serum sodium values (in the range 125–130 mmol/L), that develop over a short period of time, can both be associated with signs and symptoms.⁸

Epidemiology
The vast majority of recreationally active individuals begin endurance races with a blood [Na⁺] above 135 mmol/L. Based on data pooled from 27 separate studies, encompassing 22,622 participants with a verifiable pre-race blood [Na⁺] measurement, only 0.8% (19/2262) presented with hyponatraemia prior to race start.³ ²⁹ These pooled data represent blood [Na⁺] measurements collected in seven countries and between 5 min to 72 h precompetition. This 0.8% also includes 16 questionable below-normal [Na⁺] values possibly confounded by fingerstick haemolysis²⁵ and/or outdated techniques.²³ Thus, baseline (pre-event) hyponatraemia in recreational exercisers appears to fall within the expected range for a normal population distribution (1–2%), and at a frequency well below what has been observed in individuals presenting for non-hyponatraemia-related clinical treatment situations³⁶ or in hospitalised patients.³⁷ We thereby believe that EAH largely develops during or immediately following exercise.

EAH can present in two forms: asymptomatic or symptomatic. Asymptomatic athletes with [Na⁺] <135 mmol/L have largely been detected by blood samples taken post-exercise from athletes participating in research protocols or obtained for reasons other than suspicion of EAH. Athletes with the symptomatic form of EAH can present with mild, non-specific symptoms (eg, lightheadedness, nausea) but typically present with headache, vomiting and/or altered mental status (eg, confusion, seizure) resulting from cerebral oedema (termed EAH encephalopathy or EAHE) that may³⁸–⁴⁶ or may not⁴⁷–⁵⁵ be associated with non-cardiogenic pulmonary oedema. EAHE is a life-threatening condition that has been observed across a wide variety of activities (box 1). The incidence of asymptomatic and symptomatic cases of EAH varies widely with regard to type and duration of activity, location of the event, characteristics of the participants (see risk factors) and heat or cold stress during the event.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
<th>Benefits versus risks and burdens</th>
<th>Methodological quality of supporting evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>Strong recommendation, high-quality evidence</td>
<td>Benefits clearly outweigh risks and burdens or vice versa</td>
<td>RCTs without important limitations or overwhelming evidence from observational studies</td>
</tr>
<tr>
<td>1B</td>
<td>Strong recommendation, moderate-quality evidence</td>
<td>Benefits clearly outweigh risks and burdens or vice versa</td>
<td>RCTs with important limitations or exceptionally strong evidence from observational studies</td>
</tr>
<tr>
<td>1C</td>
<td>Strong recommendation, low-quality or very low-quality evidence</td>
<td>Benefits clearly outweigh risks and burdens or vice versa</td>
<td>Observational studies or case series</td>
</tr>
<tr>
<td>2A</td>
<td>Weak recommendation, high-quality evidence</td>
<td>Benefits closely balanced with risks and burdens</td>
<td>RCTs without important limitations or overwhelming evidence from observational studies</td>
</tr>
<tr>
<td>2B</td>
<td>Weak recommendation, moderate-quality evidence</td>
<td>Benefits closely balanced with risks and burdens</td>
<td>RCTs with important limitations or exceptionally strong evidence from observational studies</td>
</tr>
<tr>
<td>2C</td>
<td>Weak recommendation, low-quality or very low-quality evidence</td>
<td>Uncertainty in the estimates of benefits, risks and burden; benefits, risk and burden may be closely balanced</td>
<td>Observational studies or case series</td>
</tr>
</tbody>
</table>

RCT, randomised controlled trial.

Box 1 Activities in which symptomatic exercise-associated hyponatraemia (EAH) has been reported. Those activities in which known deaths have occurred are noted with an asterisk (*)

Documentation of symptomatic EAH
► Endurance competitions (marathon*, canoe race*, ultramarathon, triathlon, swimming)
► Hiking*
► Military exercises*
► Police training*
► American rules football*
► Fraternity hazing*
► Bikram Yoga
► Lawn bowling

Department of Health and Human Performance, University of California, Santa Barbara, California, USA

REFERENCES

[Insert references here]
Epidemiology of asymptomatic EAH

The reported incidence of asymptomatic EAH has ranged from 0% to 51% immediately post-race. In a study of an ultramarathon, 67% of the participants were hyponatraemic (asymptomatic) at some point during the race, but only 27% finished the race with serum [Na⁺] <135 mmol/L (40% self-corrected prior to finishing the event). The highest reported incidence of asymptomatic hyponatraemia post-race has been consistently noted in 161 km ultramarathons, in which the reported incidence of EAH has ranged between 5% and 51%. The incidence of asymptomatic EAH in Ironman triathlons in different environments has been reported to range from negligible to as high as 18% and 25%. In studies on endurance cyclists, the incidence of asymptomatic EAH has ranged from 0% in a 720 km race to 12% in a 109 km race. In a 26.4 km swim, 17% of swimmers developed asymptomatic hyponatraemia. The reported incidences at the standard marathon distance run (42.2 km) have ranged from 0% to 12–13% of race finishers. Additionally, asymptomatic hyponatraemia was observed in 33% of premier league UK rugby players following an 80 min rugby competition and 70% of elite rowers during a 28-day training camp.

Symptomatic EAH generally occurs as an osmotic imbalance for all possible CF mutations was performed, as well as in a 34-year-old woman following a Bikram Yoga session and in a 39-year-old woman following a 2 h workout including tennis and weightlifting. Cases of symptomatic EAH have also been induced in two separate laboratory studies involving low-intensity exercise conducted in high ambient temperatures. Deaths from symptomatic EAH have occurred in a 25-year-old male police officer participating in a 19 km bicycle training ride and at least partially contributed to a case of fraternity hazing involving a male pledge performing callisthenics. It is likely that other cases of symptomatic hyponatraemia have either not been recognised or not been reported.

Risk factors for EAH

The major risk factors for developing EAH are listed in box 2. The single most important risk factor is sustained, excessive fluid (water, sports drinks or other hypotonic fluids) intake in volumes greater than loss through sweat, respiratory and renal water excretion so that a positive fluid balance accrues over time. Almost all cases of symptomatic EAH have occurred in individuals who have gained or maintained weight during activities in which some weight loss would represent fluid balance and euhydration. Body weight losses of <0.75 kg after a standard marathon and <1% after an 80 min rugby match have been associated with asymptomatic EAH. All sports beverages are hypotonic to plasma (typical sodium content in sports drinks is approximately 10–38 mmol/L); thus the magnitude of excessive fluid volume ingestion will overwhelm any protective effect of the beverages’ sodium content on maintaining serum [Na⁺].
From a practical standpoint, it is the smaller individuals and those who participate at a slower pace and drink more than sweat losses who are more likely to develop EAH. Although the incidence of women experiencing EAH is greater than that of men, adjusted for body mass index and racing time, the apparent sex difference is not statistically significant. Non-steroidal anti-inflammatory drugs (NSAIDs) have been implicated as a risk factor in the development of EAH, presumably by potentiating the water retention effects of arginine vasopressin (AVP) at the level of the kidney collecting duct. However, data are conflicting, and further investigation is necessary to determine whether NSAID usage—with respect to both classification and dosage—is a risk factor for the development of EAH. The possible pathophysiological contributions of intrinsic renal disease and low solute diets on water retention, high sweat sodium concentrations in extreme environments and the potentiation of thirst by non-osmotic stimuli during exercise warrant further investigation as secondary risk factors for EAH. Whether common medications that are associated with hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in the general population, such as selective serotonin reuptake inhibitors, can potentiate the development of EAH is not known and warrants further investigation.

There is a paucity of evidence suggesting that those developing symptomatic EAH have either been a ‘salty sweater’ or a heterozygous carrier of the CF genotype. Athletes with homozygous CF, however, are at risk for developing hyponatraemia, as demonstrated by numerous instances when an individual is diagnosed with CF after the development of hyponatraemia during prolonged physical exertion or prolonged exposure to high ambient temperatures. As individuals with CF experience a longer lifespan (median predicted survival age in 2012 was 41.1 years and are encouraged to consider exercise as one of their therapies, this population may be at increased risk for EAH due to the combination of high sweat fluid and sweat [Na+] loss.

Aetiology and pathophysiology of EAH

The predominant pathophysiology of EAH, and of most serious medical concern, is dilutional hyponatraemia caused by sustained overdrinking and AVP induced impaired water clearance, which overwhelms the ability of the kidney to excrete the excess water load. Dilutional hyponatraemia is the primary pathophysiological variant of clinically symptomatic EAH and largely (if not exclusively) associated with all reported cases of morbidity and mortality listed in box 1. Dilutional EAH is an acute onset form of hyponatraemia, which is now occurring in non-endurance sports, with three deaths recently reported among the approximately 7.5 million American high school football player-years from 2008 through the 2014 seasons. These football players were encouraged to ingest copious volumes of hypotonic fluids and sports drinks to prevent or relieve exercise-associated muscle cramps (EAMC), in the belief that EAMC was caused by dehydration and electrolyte imbalance. However, experimental and observational studies speculate that EAMC may reflect neurological changes due to fatigue rather than uncompensated water and sodium losses incurred during exercise in some cases. Muscle cramping and tremor have also been associated with overdrinking and hyponatraemia in athletes, clinical populations and animals.

Symptoms associated with EAH are due to osmotically induced shifts of water into the intracellular compartment. In the confined space of the cranial, these shifts of water into the central nervous system (CNS) tissues lead to cellular oedema and pathological increases in intracranial pressure. Acutely, this may manifest in symptoms previously described, and in the extreme, may lead to brain stem herniation and death.

Aetiology of euovoltaemic/hypovoltaemic EAH

Total body water expansion relative to the amount of total body exchangeable sodium is the main pathogenic cause of asymptomatic and symptomatic EAH. Dilutional EAH can be euovoltaemic (total body water expansion without changes in total exchangeable sodium) or hypovoltaemic (total body water expansion above concomitant increases in total exchangeable sodium). The primary aetiological factor in dilutional hyponatraemia is consumption of fluids (water, sports drinks or other hypotonic fluids) in excess of total body fluid losses, which includes the sum of insensible (cutaneous, respiratory and gastrointestinal), sweat and renal (urine) fluid losses.

Hyponatraemia caused solely by the overconsumption of fluids, above known maximal urine excretory rates of 800–1000 mL, has been demonstrated at rest in athletes with and without a history of EAH. Although some cases of EAH may be due to pure water intoxication from overconsumption of fluids, non-osmotic AVP secretion is a key contributing factor in most athlete-related symptomatic cases. Known stimuli to AVP secretion that are commonly associated with exercise include: nausea/vomiting; plasma volume contraction; hypoglycaemia; elevated body temperature; and/or other hormonal mediators. Even small increases in circulating AVP levels can markedly reduce renal water excretion well below maximal levels, resulting in retained body water not only when drinking rates do not exceed those necessary to prevent excessive dehydration, but also when drinking rates are well in excess of fluid replacement need.

Summary statement: The primary aetiology and pathophysiological mechanism underlying EAH—and all known fatalities—is the overconsumption of hypotonic fluids relative to exchangeable sodium likely in combination with non-osmotic AVP secretion (Grade 1A).

Aetiology of hypovoltaemic EAH

There is persisting debate as to the relative contribution of under-replaced sodium losses to the lowered sodium concentrations observed in EAH. While in clinical medicine, electrolyte depletion without expansion of total body water or hypovoltaemic hyponatraemia is well described, in EAH this variant has been more difficult to define and is much less likely to be encountered except in extreme events usually over prolonged periods (such as ultramarathons), or hot Ironman distance triathlons. The data regarding sodium losses during exercise (as measured during recovery) and their potential contribution to the development of symptomatic hyponatraemia in longer and hotter races, have been consolidated in table 2 against data collected from relatively shorter and cooler races where fluid overload hyponatraemia has been verified. From the standpoint of the clinical literature, hypovoltaemic hyponatraemia reflects a loss of total body exchangeable sodium that manifests as volume depletion, in athletes exercising for longer periods of time (such as 161 km ultramarathons; >20 h), and/or in hotter environments, and/or with higher sweat sodium losses. Clinical confirmation of the hypovoltaemic form of hyponatraemia is supported by a spot urine sodium concentration (U[Na+]t).
Consensus statement

Table 2  Comparisons of sodium and fluid balance measured during the recovery period after exercise demonstrating race characteristics and biochemical differences between fluid overload hyponatraemia (Irving et al, Speedy et al, and Speedy et al) versus suspected hypovolaemic hyponatraemia (Owen et al)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of EAH participants (classification)</td>
<td>8 (symptomatic)</td>
<td>7 (symptomatic)</td>
<td>2 (asymptomatic)</td>
<td>26 (asymptomatic)</td>
</tr>
<tr>
<td>Peak race temperature (°C)</td>
<td>NR</td>
<td>21</td>
<td>21</td>
<td>33</td>
</tr>
<tr>
<td>Mean exercise duration (h)</td>
<td>&lt;11 (mean NR)</td>
<td>12</td>
<td>13/12 (case 1/case 2)</td>
<td>22</td>
</tr>
<tr>
<td>Monitored recovery time (h)</td>
<td>16</td>
<td>11.6</td>
<td>11.7/3</td>
<td>1</td>
</tr>
<tr>
<td>Presenting U[Na+] (mmol/L)</td>
<td>NR</td>
<td>17* (41 controls)</td>
<td>NR</td>
<td>15 pre-trial (22.3 post-trial)</td>
</tr>
<tr>
<td>Presenting BUN (mg/dL)</td>
<td>15+ pretrial (9.8 post-trial)</td>
<td>NR</td>
<td>NR</td>
<td>31 (pre-trial and post-trial)</td>
</tr>
<tr>
<td>Body sodium retained (mean value)</td>
<td>48%</td>
<td>–84 mmol (0 mmol control)</td>
<td>34%/0%</td>
<td>96%</td>
</tr>
<tr>
<td>Excess fluid excreted† (mL)</td>
<td>+2953</td>
<td>+1670 (–441 control)</td>
<td>+1500+2500</td>
<td>+20</td>
</tr>
<tr>
<td>Presenting serum [Na+] (mean±SD)</td>
<td>122±2</td>
<td>127±4</td>
<td>131±30</td>
<td>131±3</td>
</tr>
<tr>
<td>Body weight change (post-race—pre-race) (%)</td>
<td>NR</td>
<td>NR</td>
<td>+0.9/+2.5</td>
<td>−2.4±3.1</td>
</tr>
</tbody>
</table>

*All but one of these seven athletes with EAH were released from the hospital with hyponatraemia.
†EAH data compared with control group of normonatraemic triathletes partaking in the same event.
‡This represents the amount of sodium retained by the body and expressed as a percentage of the total amount of sodium that was administered during the monitored recovery period (sodium deficit/sodium given). In Speedy et al, this was expressed as a positive or negative amount (mmol) of sodium administered so that a negative value reflected the amount of sodium retained by the body ([Na+] output minus Na+ input).
§This represents the amount of fluid excreted (urine volume) during the recovery period compared with the amount of fluid that was administered during the recovery period.

BUN, blood urea nitrogen; EAH, exercise-associated hyponatraemia; NR, not reported in the manuscript.

below 30 mmol/L, in conjunction with a serum or plasma [Na+] below 135 mmol/L. A spot U[Na+] <30 mmol/L is 100% specific and 80% sensitive for predicting a sustained increase (>5 mmol/L) in serum [Na+] following isotonic saline administration in clinical patients. Elevated blood urea nitrogen levels (>20 mg/dL) and weight loss may also suggest volume depletion as a pathogenic contributor to EAH. However, these biochemical tests are not always available at the point of care and thus clinical assessment (vital signs, weight change and physical examination) may be the only indication of volume depletion.

Summary statement: Under-replaced sodium losses contribute to serum [Na+] independent of distance (Grade 1A). However, there is a paucity of data supporting sodium loss as the primary mechanism of symptomatic EAH even in those who exercise for prolonged periods of time and in warm weather (Grade 2C). In our collective experience, EAH is best classified by clinical severity (symptoms) and not the absolute numerical [Na+] value to best guide treatment strategies.

The role of thirst
Since drinking fluid volume above sweat and urinary losses during and after activity is the main pathophysiological mechanism underlying asymptomatic, symptomatic and fatal cases of EAH, prevention is dependent on drinking less. Thirst should provide adequate stimulus for preventing excess dehydration and markedly reduce the risk of developing EAH in all sports. Physiologically driven thirst has been defined as a “generalised, deep-seated feeling of desire for water,” and is an evolutionarily conserved, finely tuned regulatory mechanism serving to protect both plasma osmolality and circulating plasma volume. Osmoreceptors (highly vascularised structures located around the third and fourth ventricles, and characterised by the lack of a blood–brain barrier; they are points of communication between the blood, the brain parenchyma and the cerebral spinal fluid) located within the circumventricular organs of the brain and baroreceptors located within the aortic arch, carotid sinuses and great veins provide ‘real-time’ neural input to higher centres of the brain, which continuously and simultaneously coordinate the regulation of both thirst and AVP secretion. Thus, there are physiological sensing mechanisms in place to prompt when to drink and therefore guard against excessive dehydration. Earlier published recommendations to begin drinking before thirst were largely meant for situations where sweating rates were high, above maximal rates of gastric emptying, and dehydration would rapidly accrue over time. Unfortunately, this advice has fostered the misconception that thirst is a poor guide to fluid replacement, and has facilitated inadvertent overdrinking and pathological dilutional EAH.

Clinical classification and diagnosis of EAH
The diagnosis of EAH is made when the blood, serum or plasma [Na+] is below the normal range reference of the laboratory performing the test (typically <135 mmol/L), and is associated with a typical clinical constellation of symptoms and signs. In our collective experience, EAH is best classified by clinical severity (symptoms) and not the absolute numerical [Na+] value to best guide treatment strategies.

Characteristics of asymptomatic EAH
Asymptomatic EAH represents a biochemical finding, diagnosed by blood electrolyte testing for research or unrelated metabolic screening purposes. This group of participants presents without any discernable symptoms, or may have mild, generalised and transient symptoms commonly experienced by other participants who do not typically seek medical care following exercise. In normally distributed populations, up to 5% of all athletes tested would fall outside of the normal range for [Na+], with half of those (2.5%) falling in the range of asymptomatic EAH values.

Characteristics of mild EAH
Mildly symptomatic EAH typically presents with non-specific signs and symptoms without clear signs of encephalopathy. Athletes with mild EAH may have normal vital signs and may not have any orthostatic hypotension; also, the symptoms do not resolve after placing athletes in the Trendelenburg position, as would be expected with exercise-associated postural hypotension. The clinical symptoms of mild symptomatic EAH are not specific or sensitive, but should raise the index of suspicion for EAH and necessitate a low threshold for [Na+]...
Consensus statement

Box 3 Signs and symptoms of mild and severe (life-threatening) exercise-associated hyponatraemia (EAH). Signs and symptoms related to other conditions associated with exercise-associated collapse noted with an asterisk (*)

Symptoms and signs associated with mild EAH
- Lightheadedness*
- Dizziness*
- Nausea*
- Puffiness
- Body weight gain from baseline

Symptoms and signs associated with severe EAH and EAH encephalopathy (EAHE)
- Vomiting*
- Headache*
- Altered mental status* (confusion, disorientation, agitation, delirium, feelings of “impending doom”, obtundation)
- Phantom running
- Seizure*
- Coma*
- Signs of impending brain herniation (decorticate posturing, mydriasis)
- Dyspnoea (non-cardiogenic pulmonary oedema)
- Frothy sputum (non-cardiogenic pulmonary oedema)

Symptoms and signs associated with severe EAH and EAHE
- Confusion
- Impending doom
- Impending brain herniation
- Seizure
- Planter clonus
- Decorticate posturing
- Mydriasis
- Cardiovascular collapse
- Mental status changes
- Lightheadedness
- Puffiness
- Nausea
- Vomiting
- Dizziness
- Severe headache

Characteristics of severe EAH (EAHE)
Severe symptomatic EAH is characterised by neurological signs and symptoms due to cerebral oedema that occur when water flows along the osmotic gradient from the extracellular fluid into the intracellular compartment (box 2). Early dehydration and electrolyte imbalance may not be accompanied by the respiratory distress of CNS-triggered non-cardiogenic pulmonary oedema (box 3). EAHE is a life-threatening condition that requires urgent intervention and should be evaluated with an immediate [Na+] measurement if available.

Summary statement: EAH can present with a wide range of symptoms ranging from non-specific mild symptoms to severe encephalopathy. The severity of symptoms and not the absolute value of the [Na+] should guide the choice of therapy (Grade 1A). Rapid determination of [Na+] is critical in confirming clinical suspicion but may not always be available.

Treatment of EAH
Any athlete exhibiting signs or symptoms consistent with acute hyponatraemia (box 3) should be screened for EAH. The capacity for onsite [Na+] analysis is optimal for management of EAH and is recommended for any large-scale endurance event. However, this capability is not always practical or possible (eg, small or remote events). Treatment should be based on the degree of neurological impairment, not simply the [Na+] level, as brain oedema is dependent on both the magnitude and rate of fall of [Na+], not just the lowest level reached, as stated previously. The following treatment protocols are recommended for EAH and EAHE based either on [Na+] measurement and clinical assessment or clinical assessment alone if [Na+] measurement is not available.

Onsite treatment of asymptomatic EAH found via [Na+] measurement
Asymptomatic hyponatraemia is not normally detected unless an athlete has blood electrolyte concentrations tested for some other reason. In athletes with this incidental biochemical diagnosis, oral or intravenous hypotonic fluid intake should be restricted until the onset of urination (which suggest that AVP levels have fallen and that the urine is dilute) to reduce the risk of further decreasing [Na+] with continued AVP-mediated water retention. Furthermore, isotonic intravenous fluids should be administered with great caution or withheld until urination as, in the setting of elevated AVP levels and concentrated urine, these fluids may lower the [Na+] or delay recovery.

Although there is no compelling reason to actively treat asymptomatic EAH, it is clinically appropriate to administer oral hypertonic saline (HTS) solutions to reduce the risk of progression to symptomatic hyponatraemia; this is particularly relevant for those with a [Na+] < 130 mmol/L. On departure from the event site, athletes with asymptomatic EAH should be advised to seek urgent medical attention if any neurological signs or symptoms of EAH develop within 24 h after event completion, since delayed-onset symptomatic EAH may frequently occur. Ideally, an athlete with asymptomatic EAH should have a companion on discharge from the medical area to observe the affected athlete for signs and symptoms of evolving EAH, since the neurological impairments associated with EAH may limit the athlete’s ability to accurately self-assess his or her own status.

Summary statement: The major clinical relevance of asymptomatic EAH lies in its potential for asymptomatic athletes to quickly transition and progress into symptomatic stages if hypotonic fluids are given intravenously or ingested (Grade 1C). Thus, in patients identified with EAH, hypotonic or isotonic fluids should be withheld until urination is documented (Grade 1C).

Onsite treatment of symptomatic EAH found via [Na+] measurement
Severe EAH (EAHE)
Acute severely symptomatic hyponatraemia is a rapidly progressing, life-threatening emergency that requires immediate administration of intravenous HTS (such as 3% sodium chloride). Because EAH is an acute rather than chronic process, athletes presenting with symptomatic hyponatraemia can and should be treated with HTS as there is no risk of osmotic demyelination after exposure to HTS, but there is...
Consensus statement

Intravenous Hypotonic Saline (HTS) Therapy for Exercise-Associated Hyponatraemia (EAH)

EAH is a potentially life-threatening condition, with a grave risk of brain herniation and non-cardiogenic pulmonary oedema if HTS is not administered. Any athlete with EAH associated with signs or symptoms of encephalopathy should be immediately treated with an intravenous bolus or infusion of HTS to acutely reduce brain oedema, with additional intravenous boluses administered until there is clinical improvement. The dose and route of HTS administration should be based on the severity of clinical symptoms and the available HTS formulations, as discussed in box 4. Numerous case reports and case series have validated the efficacy and safety of intravenous HTS administration in symptomatic EAH, with one runner receiving 950 mL of 3% over a 7 h period without complications and a swimmer receiving 40 mL of 20% HTS without complication.

In the event that an athlete presents with symptoms of severe, life-threatening encephalopathy (eg, seizures, coma or signs of impending brain herniation), it is acceptable and highly recommended to administer the first bolus of HTS before [Na+] is measured. Confirmed symptomatic dilutional (euvolaemic or hypervolaemic) EAH is a contraindication to the administration of intravenous hypertonic fluids, lactated Ringer’s, or isotonic (normal) saline, all of which can worsen the degree of hyponatraemia or delay recovery.

The efficacy of intravenous HTS as the definitive treatment of acute hyponatraemic encephalopathy has been validated extensively in hospital and in field settings since it was first used successfully in 1938. This treatment is based on the capacity of an intravenous HTS bolus to increase the serum [Na+] 2–5 mmol/L, resulting in a concomitant decrease of intracranial pressure and improvement in symptoms. This approach does not pose any substantial danger to the patient, because osmotic demyelination syndrome has not been associated with either the rapid correction of acute hyponatraemia (ie, <48 h duration) in clinical or exercise settings or with the limited increase in [Na+] produced by a single bolus of HTS. Also, of note, if the athlete was wrongly assumed to have EAHE, the administration of HTS in small boluses is not associated with any negative consequences and serves as an excellent volume expander.

The goal of this therapy is to stabilise the athlete for transfer to an advanced medical care facility for further evaluation, monitoring and treatment. Ideally, the athlete should be transported with knowledgeable medical personnel from the event who are able to maintain the same level of care en route and to ensure that the treatment is not interrupted for evaluation such as CT of the brain or treatments that may worsen hyponatraemia, such as administration of hypertonic fluids, lactated Ringer’s, or isotonic (normal) saline. The diagnosis of EAHE must be communicated to the receiving physician on transfer of care.

Summary statement: For those athletes presenting with signs and symptoms consistent with EAHE, emergent intravenous treatment with HTS is indicated and should not be delayed pending laboratory measurement or other diagnostic testing (Grade 1B).

Mild EAH

Any athlete with mild EAH symptoms (box 4) may be treated with an intravenous bolus of HTS as described above. Alternatively, a mildly symptomatic athlete may be treated with oral hypertonic solutions when tolerated or observation until urination, as seen in clinical settings. Oral sodium tablets may not be as efficacious as hypertonic solutions, as suggested in a single case report, and requires further investigation. The efficacy and tolerance of oral HTS has been supported by limited field studies and may offer practical advantages in some settings (eg, where intravenous HTS or intravenous access is not available). In contrast to athletes with severe EAH, those with mild symptoms may be discharged from onsite medical care once symptoms have resolved and spontaneous urination has occurred. Repeat measurement of [Na+] is generally not required unless the patient has persistent symptoms after the initial treatment. As is recommended for asymptomatic EAH, on departure from the event site, athletes should be advised to seek urgent medical attention if any signs or symptoms of EAH develop after discharge, and ideally should have a companion capable of monitoring for signs and symptoms of which the athlete may not be aware.

Summary statement: Athletes presenting with mild symptoms associated with EAH can be treated with an intravenous bolus of HTS (Grade 1B), oral HTS fluids or observation until the onset of urination, as dictated by clinical symptoms (Grade 2B).

Onsite treatment of EAH suspected clinically but unable to confirm via [Na+] measurement

The situation may arise where EAH is strongly suspected based on the clinical evaluation of the athlete (ie, history and physical examination showing neurological symptoms or signs of EAH; box 2), but where [Na+] cannot be determined, such as in a remote setting. In this situation, empiric treatment is justified using the same treatment recommendations described above for EAHE documented with a [Na+] measurement (box 4). This empiric approach can be life-saving and is...
unlikely to do harm, since: (1) the additional small increase in serum osmolality from a single bolus of HTS will not significantly worsen the neurological status and (2) a bolus of HTS will expand the intravascular volume by increasing the serum [Na⁺], partially reducing any hypovolaemic component of the hyponatraemia. 139

In-hospital treatment of symptomatic EAH

Athletes presenting to a hospital or medical facility, whether primarily or as a transfer from the event site, with signs or symptoms of hyponatraemia, will require immediate measurement of electrolytes and should be treated as described above without delay once EAH is confirmed (box 4). If symptomatic EAH persists or worsens following the initial intervention with intravenous HTS, current treatment guidelines for acute symptomatic hyponatraemia should be instituted and the patient managed in an intensive or critical care setting with care provided or guided by a specialist familiar with this life-threatening condition. 56

Summary statement: Athletes presenting to a medical facility with EAH should be treated as per other settings (Grade 1C). However, diagnostic testing in these scenarios should not delay potentially life-saving therapy with HTS (Grade 1C).

Table 3 Thirteen studies representing 41 cases of symptomatic EAH that provided comment on drinking plan or motivation for chosen drinking behaviours

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Subjects, age (years old) sex (♂/♀) activity</th>
<th>Serum [Na⁺] mmol/L (initial or range)</th>
<th>Symptomatic EAH with drinking above thirst (comments from report)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frizzell et al (1986)40</td>
<td>24♂/45♀ Ultra runners</td>
<td>123/118</td>
<td>Runners as a group, are taught to “push fluids” Athletes are instructed to drink more than their thirst dictates, since thirst may be an unreliable index of fluid needs during exercise</td>
</tr>
<tr>
<td>Armstrong et al (1993)48</td>
<td>21♀ Lab subject</td>
<td>122</td>
<td>Voluntarily consumed this large volume of fluid because he believed that drinking water copiously would decrease his risk of heat illness</td>
</tr>
<tr>
<td>Herfel et al (1998)41</td>
<td>22♂ Football player</td>
<td>121</td>
<td>He was diagnosed with muscle cramps secondary to dehydration. Therefore, five liters (L) of 0.45% normal saline in 5% dextrose was administered intravenously along with 3 L of liquids by mouth over a five hour period</td>
</tr>
<tr>
<td>Reynolds et al (1998)189</td>
<td>6♂ (90.2♂) Soldiers</td>
<td>118–134</td>
<td>Consuming large volumes of water as “protection against becoming a heat casualty” predisposed these troops to the physical impairment that they intended to avoid</td>
</tr>
<tr>
<td>Backer et al (1999)73</td>
<td>7♂ (61.1♂) Hikers</td>
<td>109–127</td>
<td>Most patients diagnosed as having hyponatraemia have a distinct history of high fluid intake… Unlike heat exhaustion patients, few of our hyponatremic patients were thirsty when evaluated, perhaps because they drank more fluids and were hyperhydrated</td>
</tr>
<tr>
<td>Garigan et al (1999)46</td>
<td>18♂ Soldier</td>
<td>121</td>
<td>Complained of thirst, drank 3 quarts, then vomited...told to drink 1 quart every 30 minutes With encouragement by unit members, he consumed 10 quarts of water during the next 90 minutes</td>
</tr>
<tr>
<td>Hew et al (2003)43</td>
<td>21♂ (90.8♂) Marathon runners</td>
<td>117–134</td>
<td>Advice given to runners was “drink until your urine is clear” and “do not wait until you are thirsty to drink”</td>
</tr>
<tr>
<td>Dimoff (2006)40</td>
<td>27♂ Football player</td>
<td>116</td>
<td>Complained of feeling ill...encouraged to consume sports drinks Admits to drinking 2–3 gallons water every day because he had been taught that “water is the best replacement fluid” and because that is what he was advised to do growing up in Texas</td>
</tr>
<tr>
<td>Hew-Butler (2007)8</td>
<td>41♂ Ironman triathlete</td>
<td>132 (nadir)</td>
<td>Subject reports he was never thirsty, but drank to “stay ahead of thirst”</td>
</tr>
<tr>
<td>Draper (2009)49</td>
<td>37♀ Marathon runner</td>
<td>117</td>
<td>She followed a strategy (as advised by fellow experienced marathon runners) to begin the race “well-hydrated” (drinking greater volumes than her thirst dictated) Warnings were issued over the public address system at the race start relating to ensuring a high intake of fluids was maintained</td>
</tr>
<tr>
<td>Rothwell and Rosengren (2008)118</td>
<td>43♂ Hiker</td>
<td>107</td>
<td>Complained of abdominal pains and leg cramps for 24 hours leading up to collapse On the evening before and day of collapse, fellow trekkers and guides encouraged him to drink large amounts of water</td>
</tr>
<tr>
<td>Coler et al (2012)151</td>
<td>85♀ Hiker</td>
<td>120</td>
<td>Subject was encouraged to…”Push fluids” above thirst</td>
</tr>
<tr>
<td>Rogers (2015)51</td>
<td>46♂ Swimmer</td>
<td>118</td>
<td>Her intended fluid regimen…was 200 mL of fluid every 20 minutes She reported no sensation of thirst throughout the race Although she did not feel thirsty, she was encouraged to drink by the support staff</td>
</tr>
</tbody>
</table>

*Case reports involving multiple subjects: total number of subjects (number of female/male subjects). EAH, exercise-associated hyponatraemia.
Consensus statement

pathological dilutional EAH, as demonstrated in 41 cases evaluated in table 3.

Modest to moderate levels of dehydration are tolerable and pose little risk to life in otherwise healthy individuals. Laboratory and field studies indicate that fluid deficits less than and up to a volume approximately equal to 3% of normal body mass (or ∼5% total body water) can be tolerated without a reduction in endurance performance or muscular power when in cool to temperate (−10°C to 20°C) temperatures. Therefore, aggressive drinking to prevent dehydration is unnecessary and carries with it greater risk of developing symptomatic EAH.

Body weight is a reasonable surrogate measure of hydration state when measured day to day after sleep, and can be used to relatively accurately assess changes in hydration state accompanying upwards to 1–2 h of activity. However, it is a very imprecise measure during those athletic events where EAH is most likely to develop, that is, multiple hours of sustained activity. This is in large part due to body mass changes accompanying energy combustion and unknown amounts of food consumed, bathroom stops, etc. Moreover, consolidation of four studies (786 athletes) comparing body weight changes taken at registration (1–3 days prior) and again within 60 min of race start demonstrate an average of 1% increase in body weight from registration to race start. However, this average value conceals the fact that large gains in weight (up to at least 4% of body mass) occur in some individuals while substantial weight losses occur in others over the last day or two before competition. This weight increase further confounds the accuracy of bodyweight as a proxy measure of body water in field events. With that said, a body mass measured after several hours of activity that is equal to or above the individuals’ normal body mass, is a positive indicator for the presence of fluid overload.

The safest individualised hydration strategy before, during and immediately following exercise is to drink palatable fluids when thirsty (figure 1). Marathon runners with hypernatraemia report ‘thirstiness’ as a physiologically expected symptom, while a weak but statistically significant relationship has been demonstrated between thirst ratings and plasma [Na+] immediately following a 161 km race. Studies verify that participants allowed free access to fluids during treadmill walking in the heat or running 30 km under different ambient conditions maintain body osmolality by drinking to thirst. Moreover, the cues to drink provided by osmolality and blood volume, persist in hot as cold environments. Thus, drinking to thirst will, in most cases, prevent both dilutional EAH and performance decrements due to excessive dehydration. Potential exceptions to this fluid replacement strategy are thirst stimulated by confounding oral variables such as dry mouth (xerostomia), genetic influences, known discrepancies between drinking ‘ad libitum’ versus drinking according to the dictates of thirst, excessive sodium intake and/or other non-osmotic or hypovolaemic factors that are yet to be determined, and require further investigation (table 4). Given that excessive fluid consumption is a primary aetiological factor in EAH, using the innate thirst mechanism to guide fluid consumption is a strategy that should limit drinking in excess and reduce the risk of developing hypernatraemia while providing sufficient fluid to prevent excessive dehydration (Grade 1C).

Additional strategies to prevent EAH

Sodium supplementation

When fluid intake matches or even slightly exceeds sweat losses, the ingestion of sodium-containing sports drinks can attenuate the rate of fall of [Na+] over the course of 2 h of continuous or intermittent cycling and approximately 4 h of running. However, it is critical to emphasise that sodium-containing sports drinks, which are hypotonic, will not prevent EAH in athletes who overdrink during exercise, as all sports drinks have a significantly lower [Na+] (10–38 mmol/L) than serum (∼140 mmol/L). The dilutional effect of volume excess overwhelms any positive effect of sodium and electrolytes in sports drinks. Therefore, while modest salt replacement is likely not harmful and has been associated with significant increases or no change in serum [Na+] during competitive field events, it will be of modest to no benefit in situations where excess fluids are being consumed. The potential detrimental effects of excessive sodium supplementation are not clear.

Summary statement: Sodium supplementation is a strategy for attenuating sodium concentration reductions that can develop when fluid intakes approximate sweat losses during prolonged exercise but cannot prevent EAH in the setting of a persistent excessive fluid intake that produces fluid overload (Grade 1C).

Education and event management efforts

Athlete and support team educational strategies should be instituted to improve knowledge of safe hydration practices and reduce the overemphasis on high fluid intakes. For example, an education programme for an Ironman triathlon advising athletes of the risks incurred by overdrinking, coupled with decreasing the number of fluid stations to limit the fluid availability, reduced the incidence of EAH. Dissemination of appropriate drinking advice alone has also been shown to reduce the incidence of EAH in a 90 km footrace.

Past studies have demonstrated that cycling fluid stations placed 20 km apart in an Ironman triathlon and running fluid stations placed 5 km apart in a standard marathon have reduced or prevented EAH. However, this proposed strategy and its effect on the incidence of EAH needs further study to determine the optimal number and spacing of fluid stations in different terrains and ambient temperatures. Furthermore, alternative strategies will be needed in settings where EAH has been noted but aid stations are not provided, or in situations where drinks are freely available and/or athletes transport their own fluids.

Athletes who seek more quantitative guidance are encouraged to weigh themselves before and after training to assess their sweating rates and fluid replacement needs. Some weight loss associated with activity will be unrelated to fluid status, as non-water mass is lost as energy is expended (approximately

Figure 1 Primary recommended fluid intake strategy to prevent symptomatic exercise-associated hyponatraemia (EAH).
and is increased with increasing duration and intensity of exercise. The presence of weight gain is a positive indicator that fluid intake has been in excess of fluid losses and water overload is present.

**Summary statement:** Educational efforts regarding the risks of overhydration should be encouraged and disseminated widely to athletes, coaches and event management personnel (Grade 1C). These efforts should include all sporting events where EAH has been encountered. Event management strategies such as limiting access to fluids may be of benefit, but require broader study.

**Dissemination of advice for prevention and treatment of EAH**

Athletes, coaches, parents

Educational strategies and programmes are needed that effectively communicate to coaches, athletes and parents: rational fluid replacement, avoidance of overconsuming fluids (water, sports drinks or other hypotonic fluids), to recognise the signs and symptoms of EAH, and to understand the critical need for immediate medical attention for suspected casualties. Athletes, coaches and parents must be alert to the risks of excessive fluid consumption and understand that high fluid intakes will not necessarily prevent exercise-associated maladies such as muscle cramps or exertional heat stroke.

On-site medical professionals (medics, paramedics, emergency medical technicians, athletic trainers, physiotherapists and others)

The educational strategies for on-site medical personnel must address the circumstances (during or following events or practices during acclimatisation), identification, evaluation and management of EAH and EAHE, and emphasise that the life-threatening nature of these rare conditions requires immediate intervention. The pathophysiology of EAH and the drinking behaviours involved in the evolution of EAH must be clearly recognised. It should be stressed that: (1) EAH is caused primarily by the consumption of hypotonic fluid in excess of sweat and urinary losses and (2) excessive fluid intake (water, sports drinks or other hypotonic beverages) may not prevent muscle cramps or exertional heat stroke and, in rare cases, may even be associative.

On-site personnel must understand that oral fluid intake, and intravenous fluid infusion of hypotonic and isotonic fluids, are contraindicated in all suspected cases of EAH and rapid transfer to a hospital is necessary. The potential life-saving role of HTS requires wide-spread education and should be considered the equivalent of automatic external defibrillators and ice/cold water immersion in the ‘first aid’ of sudden cardiac arrest and exertional heat stroke, respectively.

Team physicians and medical directors of athletic events

Team physicians and medical directors of athletic events should be involved in all decisions regarding medical management, including overseeing medical protocols, medical supplies/equipment, strategies for fluid replacement that optimise safe hydration practices, placement of fluid stations and the use of intravenous rehydration. Important athletic event decisions include spacing and placement of fluid stations, distribution of fluid replacement advice to athletes, and training of the aid station personnel and spectators. Drinking advice distributed to participants by sponsors should be reviewed by and approved by the event medical team to avoid conflict with the official race educational information.

Team physicians and event medical directors should ideally have onsite point of care [Na+] analysis available and HTS on hand for management of EAH and EAHE. The event organiser/medical director should be in contact with the local emergency medical services to ensure that transportation to an advanced care medical facility is available during events with high risk for EAH (see box 1).

A record of EAH cases should be kept, including follow-up and outcome, to aid in planning for future events, and to establish both incidence and prevalence for different events.

**Emergency medical services and hospitals**

Prior to the race or athletic event, the medical team should establish a relationship with the local emergency response and transport teams, medical facilities and emergency department physicians. This may include specific collaborative education programmes aimed at all of these groups and pre-event checklists to ensure that the appropriate course of action is taken, and the needed supplies are available in the emergency room when an athlete arrives in extremis.

**Summary statement:** Prevention of EAH requires broad educational programmes with consistent messages that stress the

---

**Table 4** Four case reports describing symptomatic EAH while drinking either ad libitum (two cases) or in response to thirst (two cases)

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Subjects (type)</th>
<th>Plasma [Na+] mmol/L (initial)</th>
<th>Symptomatic EAH with ad libitum drinking</th>
<th>Symptomatic EAH with drinking in response to thirst</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baker et al (2005)</td>
<td>65 yr Lab trial</td>
<td>126</td>
<td>46 kg drank 2.8 L water and gained 2.4 kg in 2.5 h intermittent cycling trial 30°C</td>
<td></td>
</tr>
<tr>
<td>Hew-Butler, (2012)</td>
<td>28 yr cyclist</td>
<td>114</td>
<td>Subject was not encouraged to drink but told that more fluid was readily available if needed</td>
<td></td>
</tr>
<tr>
<td>Khodaei (2013)</td>
<td>44 yr Mountain biker</td>
<td>116</td>
<td>84 kg drank 29 L water and 5.3 g sodium during plus after race (~14 h total)</td>
<td></td>
</tr>
<tr>
<td>Hoffman (2015)</td>
<td>53 yr Ultrarunner</td>
<td>122</td>
<td>Subject began using “regular sodium supplementation” and “very thirsty” at 100 km 2.2% weight gain noted at 126 km and dropped out of race at 145 km (28 h)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Age (years old)</th>
<th>Sex (♂♀)</th>
<th>Activity</th>
<th>Initial labwork in hospital: BUN=22 mg/dL</th>
<th>Labwork 2 months after hospitalisation: plasma [Na+]=133 mmol/L, BUN=19 mg/dL</th>
<th>Subject received 20 L of IV fluids in hospital and discharged with positive fluid balance of 6.6 L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baker et al (2005)</td>
<td>65 yr</td>
<td>♂♀</td>
<td>Lab trial</td>
<td>inaugural symptoms</td>
<td>Labwork 2 months after hospitalisation: plasma [Na+]=133 mmol/L, BUN=19 mg/dL</td>
<td>Subject received 20 L of IV fluids in hospital and discharged with positive fluid balance of 6.6 L</td>
</tr>
<tr>
<td>Hew-Butler, (2012)</td>
<td>28 yr</td>
<td>♂♀</td>
<td>cyclist</td>
<td>Subject followed her normal practice of ingesting a GU packet with 200 mL of water every 45 min with Coke and water ad libitum for an estimated fluid consumption rate of ~550 mL/h</td>
<td>Labwork 2 months after hospitalisation: plasma [Na+]=133 mmol/L, BUN=10 mg/dL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Age (years old)</th>
<th>Sex (♂♀)</th>
<th>Activity</th>
<th>Initial symptoms</th>
<th>Labwork 2 months after hospitalisation: plasma [Na+]=133 mmol/L, BUN=19 mg/dL</th>
<th>Subject received 20 L of IV fluids in hospital and discharged with positive fluid balance of 6.6 L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Khodaei (2013)</td>
<td>44 yr</td>
<td>♂♀</td>
<td>Mountain biker</td>
<td>Subject began using “regular sodium supplementation” and “very thirsty” at 100 km 2.2% weight gain noted at 126 km and dropped out of race at 145 km (28 h)</td>
<td>Labwork 2 months after hospitalisation: plasma [Na+]=133 mmol/L, BUN=19 mg/dL</td>
<td>Subject received 20 L of IV fluids in hospital and discharged with positive fluid balance of 6.6 L</td>
</tr>
<tr>
<td>Hoffman (2015)</td>
<td>53 yr</td>
<td>♂♀</td>
<td>Ultrarunner</td>
<td>Subject began using “regular sodium supplementation” and “very thirsty” at 100 km 2.2% weight gain noted at 126 km and dropped out of race at 145 km (28 h)</td>
<td>Labwork 2 months after hospitalisation: plasma [Na+]=133 mmol/L, BUN=19 mg/dL</td>
<td>Subject received 20 L of IV fluids in hospital and discharged with positive fluid balance of 6.6 L</td>
</tr>
</tbody>
</table>

BUN, blood urea nitrogen; EAH, exercise-associated hyponatraemia; IV, intravenous.
importance of appropriate hydration practices, recognition of EAH and proper therapy (Grade 1C).

Controversies in EAH

Hypovolaemic hyponatraemia

It is unclear whether the hypovolaemic variant of EAH has medical consequences. At present, we have apparent evidence of hypovolaemic hyponatraemia developing over the course of ultraendurance events, but we lack data regarding: (1) the relative contribution of solute deficits versus fluid status and (2) whether or not the hypovolaemic component is somehow compromising the afflicted individual. Most of the contributions of sweat and urinary sodium losses are negligible to the overall pathogenesis of EAH with the possible exception of volume depleted athletes with low serum sodium levels. Thermoregulatory sweat is hypotonic, with sweat sodium concentrations ranging between 10 and 70 mmol/L, which are well below the normal (isotonic) range of values for serum [Na+] (135–145 mmol/L). While there will always be some contribution of sodium loss to the pathogenesis of EAH—which will vary significantly in magnitude depending on: exercise intensity, exercise duration, body size and relative ambient temperature—it is not clear whether or not sweat sodium losses alone can account for the changes in hypovolaemic hyponatraemia in athletes. The potential role of urinary sodium losses from exercise-induced brain natriuretic peptide secretion contributing to EAH is also unclear. There are three distinct groups of athletes that demonstrate extreme sodium conservation, which may increase the susceptibility towards the development of hypovolaemic hyponatraemia: (1) runners participating in 161 km races under hot conditions; (2) Ironman triathletes participating in hot and humid Ironman triathlons and (3) football players during the first week of training camp. These three groups would hypothetically be at greater risk for developing the hypovolaemic variant of EAH from more vigorous and sustained sweating (and associated sweat sodium and potassium losses), coupled with an inability to eat sufficient foods to offset the sodium and potassium losses. Football players may also lack adequate adaptations to heat stress at the onset of pre-season training, which would prevent excessive sweat sodium losses with repeated exposure.

Treatment of hypovolaemic hyponatraemia: Participants with suspected hypovolaemic EAH and developing signs of encephalopathy would be best treated initially with an intravenous HTS bolus to reverse intracerebral oedema and expand the intravascular volume. The initial bolus of HTS can be followed by intravenous 0.9% saline, if neurological symptoms improve. At least one panel member has successfully treated athletes who were clinically volume depleted, with measures of [Na+] as low as 124 mmol/L, with intravenous normal saline infusion. As in all cases of EAH, it would be harmful to treat with hypotonic intravenous solutions.

Clinical importance of asymptomatic EAH

The clinical relevance of the asymptomatic form of EAH continues to be disputed. We agree that the main clinical relevance of asymptomatic EAH lies in the potential for asymptomatic athletes to transition to symptomatic EAH with the continued ingestion of hypotonic fluids. Moreover, symptomatic EAH can rapidly progress to life-threatening symptomatic hyponatraemia if large volumes of hypotonic fluids are ingested after identification of asymptomatic EAH, or are administered intravenously during recovery from exercise.

SUGGESTIONS FOR FUTURE RESEARCH

Propective and controlled clinical trials should be performed both in the laboratory and in the field to best determine optimal preventative and therapeutic strategies. Some of the remaining issues for study include:

- Examining nutritional requirements and/or role of diet on the risk for EAH.
- Examining tolerance versus risk for various forms (tablets vs solution) and amounts of sodium supplementation on health, performance and natraemia status.
- Gathering evidence with regard to the success of the ‘drink to thirst’ strategy on prevention and/or reduction of the incidence of EAH in athletic events.
- Determining if the development of EAH increases the risk for recurrence and/or long-term health problems.
- Identifying genetic markers that may predispose individuals in developing EAH.
- Additional research is necessary to understand whether individuals consuming NSAIDs are at heightened risk of developing EAH.
- Investigating the efficacy of alternative treatments for non-life-threatening EAH, including oral hypertonic sodium solutions, sodium tablets and vasopressin receptor antagonists.
- Clarifying the aetiology behind the apparent hypovolaemic trait of EAH and the potential for pathophysiological consequences.
- Evaluating the variability in [Na+] in the days leading up to the event, at event start and during the event.
- Evaluating the variability in body weight in the days leading up to the event and at event start.

SUMMARY OF RECOMMENDATIONS

A. Aetiology of EAH

1. The primary aetiology and pathophysiological mechanism underlying EAH—and all known fatalities—is the overconsumption of hypotonic fluids relative to exchangeable sodium in likely combination with non-osmotic AVP secretion (Grade 1A).

2. Under-replaced sodium losses contribute to serum [Na+] independent of distance (Grade 1A). However, there is a paucity of data supporting sodium loss as the primary mechanism of symptomatic EAH even in those who exercise for prolonged periods of time and in warm weather (Grade 2C). In these cases, relative overdinking of hypotonic fluids with sustained non-osmotic AVP secretion is likely involved in the development of symptomatic EAH.

B. Clinical classification and diagnosis of EAH

1. EAH can present with a wide range of symptoms ranging from non-specific mild symptoms to severe encephalopathy. The severity of symptoms and the absolute value of the [Na+] should guide the choice of therapy (Grade 1A). Rapid determination of [Na+] is critical in confirming clinical suspicion but may not always be available.

C. Treatment of EAH

1. The major clinical relevance of asymptomatic EAH lies in its potential for asymptomatic athletes to quickly transition progression into symptomatic stages if hypotonic fluids are given intravenously or ingested (Grade 1C). Thus, in patients identified with EAH, hypotonic or isotonic fluids should be withheld until urination is documented (Grade 1C).
2. For those athletes presenting with signs and symptoms consistent with EAHE, emergent intravenous treatment therapy with HTS is indicated and should not be delayed pending laboratory measurement or other diagnostic testing (Grade 1B).

3. Athletes presenting with mild symptoms associated with EAH can be treated with an intravenous bolus of HTS (Grade 1B), oral HTS fluids or observation until the onset of urination, as dictated by clinical symptoms (Grade 2B).

4. Athletes presenting to a medical facility with EAH should be treated as per other settings (Grade 1C). However, diagnostic testing in these scenarios should not delay potentially life-saving therapy with HTS (Grade 1C).

D. Prevention of EAH

1. Given that excessive fluid consumption is a primary aetiological factor in EAH, using the innate thirst mechanism to guide fluid consumption is a strategy that should limit drinking in excess and developing hyponatraemia, while providing sufficient fluid to prevent excessive dehydration (Grade 1C).

2. Prevention of EAH requires broad educational programmes with consistent messages that stress the importance of appropriate hydration practices, recognition of EAH and proper therapy (Grade 1C).

Author affiliations

1 Exercise Science Program, Oakland University, Rochester, Michigan, USA
2 Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia, USA
3 Department of Sports Medicine, West Chester University, West Chester, Pennsylvania, USA
4 The Vitality Group, Chicago, Illinois, USA
5 Department of Physical Medicine and Rehabilitation, VA Northern California Health Care System and University of California Davis, Sacramento, California, USA
6 Family Medicine Residency Program, Via Christi Hospitals Wichita, Inc, Wichita, Kansas, USA
7 Department of Sport and Exercise Nutrition, Loughborough University, Leicestershire, UK
8 Athletics Training Program, Central Michigan University, Mount Pleasant, Michigan, USA
9 Military Nutrition Division, United States Army Research Institute of Environmental Medicine, Natick, Massachusetts, USA
10 School of Physical Education, Sport & Exercise Sciences, University of Otago, Dunedin, New Zealand
11 Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota, USA
12 Department of Emergency Medicine, St John of God Murdoch Hospital and University of Notre Dame, Perth, Western Australia, Australia
13 Department of Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA
14 Health Sciences Department, Gettysburg College, Gettysburg, Pennsylvania, USA
15 Department of Family Medicine, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois, USA
16 Department of Endocrinology and Metabolism, Georgetown University Medical Center, Washington DC, USA

Contributors TH-B, SF-G and MHR initiated and planned the consensus meeting. MHR chaired the workgroups and closed panel deliberations. All the authors drafted, revised and approved multiple drafts leading to the final document.

Competing interests RJM has received research funding and consulting fees from the food and beverage industry. He is currently Chair of the Science Advisory Board of the European Hydration Institute.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES


Statement of the 3rd International Exercise-Associated Hyponatremia Consensus Development Conference, Carlsbad, California, 2015


doi: 10.1136/bjsports-2015-095004

Updated information and services can be found at:
http://bjsm.bmj.com/content/49/22/1432

These include:

References
This article cites 174 articles, 32 of which you can access for free at:
http://bjsm.bmj.com/content/49/22/1432#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Editor's choice (331)
Musculoskeletal syndromes (431)
Epidemiology (164)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/